Equities

SinoMab BioScience Ltd

SinoMab BioScience Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.72
  • Today's Change-0.02 / -1.15%
  • Shares traded104.10k
  • 1 Year change-2.27%
  • Beta0.1398
Data delayed at least 15 minutes, as of Jun 14 2024 08:55 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE). The Company’s product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogren’s syndrome (SS) and other immunological diseases.

  • Revenue in HKD (TTM)1.47m
  • Net income in HKD-261.81m
  • Incorporated2001
  • Employees215.00
  • Location
    SinoMab BioScience LtdUnits 303 and 305 to 307No.15 Science Park West AvenueHong Kong Hong KongHKG
  • Phone+852 34269833
  • Websitehttps://www.sinomab.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jacobio Pharmaceuticals Group Co Ltd68.41m-386.75m1.40bn301.00--1.21--20.49-0.5003-0.50030.08851.460.0419--5.21227,264.10-23.66-45.76-26.86-49.305.04---565.36-372.22----0.1636---33.66--3.43--19.18--
Essex Bio-Technology Ltd1.71bn275.26m1.41bn1.48k5.290.73174.200.82480.46890.46892.873.390.61612.283.351,152,300.009.9411.2013.2114.7390.2086.0116.1319.771.46--0.132616.1629.517.7222.113.567.297.39
Wuhan YZY Biopharma Co Ltd0.00-206.45m1.45bn123.00--10.55-----1.11-1.110.000.7092------0.00----------------1.41-100.120.4138-------1.50------
Mabpharm Ltd93.87m-225.46m1.51bn347.00--6.82--16.04-0.0547-0.05470.02280.05360.08930.11766.02270,507.70-21.44-21.42-28.92-27.4986.32---240.19-486.400.7596-19.030.5591--55.87--0.694---26.85--
Hua Medicine82.50m-227.48m1.67bn177.00--14.22--20.22-0.2327-0.23270.08440.11110.05381.6913.03466,121.40-14.84-25.61-17.56-28.8148.78---275.73-1,654.706.06--0.6238--335.31---3.80--14.07--
Immunotech Biopharm Ltd0.00-360.58m1.70bn211.00--9.08-----0.7007-0.70070.000.36340.00----0.00-38.88-37.42-50.88-45.48--------1.03-2.510.4327-------5.25---8.46--
Cryofocus Medtech Shanghai Co Ltd44.10m-104.99m1.74bn392.00--9.98--39.36-0.4391-0.43910.18440.7272------112,500.60--------75.83---258.23--4.08--0.0597--50.83--13.13------
Dawnrays Pharmaceutical (Holdings) Ltd1.24bn351.08m1.77bn1.14k5.050.57583.931.430.23360.23360.8252.050.31562.316.371,084,603.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
Cutia Therapeutics148.21m-2.11bn1.87bn298.00--1.28--12.60-6.96-6.960.48754.78------497,349.40--------51.60---1,426.91--5.38--0.153--1,110.83---253.30------
SinoMab Bioscience Ltd1.47m-261.81m1.88bn215.00--5.59--1,277.42-0.2572-0.25720.00140.30760.0015----6,837.24-26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---11.480.604------14.45--106.81--
TOT Biopharm International Co Ltd840.68m-40.66m1.96bn551.00--2.64372.642.33-0.0561-0.05611.160.95690.58081.878.031,525,738.00-2.81-20.01-3.72-25.2173.5374.74-4.84-68.531.48-4.600.3348--76.5481.8824.36--21.04--
Frontage Holdings Corp2.03bn84.41m2.04bn1.76k24.480.76035.631.000.04090.04090.98061.320.46360.635.321,153,777.001.914.462.335.2830.1734.004.139.921.394.090.2960.003.7925.61-58.00-0.782640.43--
HighTide Therapeutics Inc0.00-1.01bn2.11bn66.00--2.56-----2.14-2.140.001.60------0.00--------------------0.0229-------393.76------
Abbisko Cayman Ltd20.53m-464.78m2.14bn258.00--1.00--104.34-0.7181-0.71810.03173.040.0083--1.4079,559.13-18.74---19.67--100.00---2,264.34------0.0177------12.92------
Laekna Inc0.00-397.19m2.23bn89.00--2.57-----3.29-3.290.002.22------0.00-------------------5.280.0655------52.81------
MicroPort CardioFlow Medtech Corp362.08m-507.81m2.29bn592.00--0.9115--6.33-0.2149-0.21490.15321.040.12052.783.67611,620.80-16.91-17.37-18.11-22.962.06-1.67-140.25-180.829.91-11.560.0293--33.94---3.77---14.16--
Data as of Jun 14 2024. Currency figures normalised to SinoMab BioScience Ltd's reporting currency: Hong Kong Dollar HKD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.